Payment overview · 2025
General Payments
$818.21
44 reported records · 18 companies
Healthcare provider profile · identity verified
John M Dipietra, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COLUMBUS, OH · NPI 1295770469
Verified facts
What the public records show
CMS Open Payments records show John M Dipietra, MD received $818.21 in general payments during 2025 across 44 reported records.
Lilly USA, LLC accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 350 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 350 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $109.80 | 13.4% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $97.82 | 12.0% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.48 | 10.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $79.42 | 9.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.63 | 9.6% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.92 | 7.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.20 | 6.8% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $47.19 | 5.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $38.15 | 4.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.13 | 3.6% | 2 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $23.55 | 2.9% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.84 | 2.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.43 | 2.4% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $17.96 | 2.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.50 | 2.0% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.34 | 1.9% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.03 | 1.7% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $13.82 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $818.21 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $97.65 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $82.34 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $82.34 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $78.63 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $78.63 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.07 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.99 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.99 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.41 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $55.20 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.20 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $47.19 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $38.15 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $29.13 | 2 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $13.82 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
350 | 67 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
350 | 67 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 784 | 197 |
| Levothyroxine Sodium | Levothyroxine Sodium | 526 | 131 |
| Lisinopril | Lisinopril | 422 | 97 |
| Simvastatin | Simvastatin | 401 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 351 | 93 |
| Eliquis | Apixaban | 350 | 67 |
| Omeprazole | Omeprazole | 333 | 95 |
| Losartan Potassium | Losartan Potassium | 324 | 90 |
| Sertraline Hcl | Sertraline Hcl | 314 | 59 |
| Gabapentin | Gabapentin | 308 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 70 |
| Metformin Hcl | Metformin Hcl | 248 | 80 |
| Carvedilol | Carvedilol | 244 | 50 |
| Furosemide | Furosemide | 237 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 224 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 75 |
| Potassium Chloride | Potassium Chloride | 199 | 44 |
| Mirtazapine | Mirtazapine | 198 | 38 |
| Trazodone Hcl | Trazodone Hcl | 180 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 42 |
| Glimepiride | Glimepiride | 177 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 173 | 51 |
| Donepezil Hcl | Donepezil Hcl | 158 | 24 |
| Nifedipine Er | Nifedipine | 154 | 30 |
| Buspirone Hcl | Buspirone Hcl | 152 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 27 |
| Finasteride | Finasteride | 146 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 144 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 138 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 37 |
| Ezetimibe | Ezetimibe | 120 | 28 |
| Metformin Hcl Er | Metformin Hcl | 112 | 31 |
| Allopurinol | Allopurinol | 104 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 20 |
| Atenolol | Atenolol | 101 | 32 |
| Bupropion Xl | Bupropion Hcl | 86 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 24 |
| Januvia | Sitagliptin Phosphate | 85 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 40 |
| Synthroid | Levothyroxine Sodium | 84 | 21 |
| Memantine Hcl | Memantine Hcl | 83 | 17 |
| Montelukast Sodium | Montelukast Sodium | 83 | 15 |
| Spironolactone | Spironolactone | 77 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 16 |
| Lovastatin | Lovastatin | 76 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 22 |
| Alprazolam | Alprazolam | 65 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 17 |
| Meloxicam | Meloxicam | 60 | 20 |
| Celecoxib | Celecoxib | 57 | 18 |
| Levetiracetam | Levetiracetam | 57 | suppressed |
| Ozempic | Semaglutide | 57 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 18 |
| Tramadol Hcl | Tramadol Hcl | 54 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 11 |
| Xarelto | Rivaroxaban | 47 | suppressed |
| Famotidine | Famotidine | 44 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 13 |
| Warfarin Sodium | Warfarin Sodium | 43 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 13 |
| Clonidine Hcl | Clonidine Hcl | 41 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 39 | suppressed |
| Digoxin | Digoxin | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 11 |
| Fenofibrate | Fenofibrate | 36 | 11 |
| Glipizide | Glipizide | 36 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 11 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 11 |
| Topiramate | Topiramate | 33 | suppressed |
| Calcitriol | Calcitriol | 32 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | 12 |
| Prednisone | Prednisone | 32 | 20 |
| Valsartan | Valsartan | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 23 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Primidone | Primidone | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | 11 |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 16 |
| Prevalite | Cholestyramine | 19 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 13 |
| Enoxaparin Sodium | Enoxaparin Sodium | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Jantoven | Warfarin Sodium | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Methimazole | Methimazole | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $818.21 · 44 records | Lilly USA, LLC | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAMZYOS, COMIRNATY, EVENITY, GVOKE HYPOPEN, Heplisav-B, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, TZIELD, UBRELVY, ULTOMIRIS, UNITHROID, WATCHMAN Access System, Wegovy, Xhance, ZAVZPRET, ZENPEP, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error